Until now the attention of the investigators in the field of biomedical aspects of urea (carbamide) was concentrated on its functions at renal level. However, the functional significance of endogenous urea at extrarenal level in mammalian organism (1) has not been satisfactory elucidated yet. Therefore a new principal question arises: which are the signals realized by endogenous urea in living animals and humans -extrarenally?
male sex. We pharmacologically characterize urea as an endogenous, nonspecific beta-adrenergic receptor antagonist (ENBARA) (2) (3) (4) (5) (6) (7) . And, conclude that the endogenous urea (under physiological and pathological conditions in animal and human organism) realizes endocoid (autacoid) potentials in cardiovascular beta-1,2-adrenergic receptors, as consequence of the molecular events leading to antagonize and diminish of receptor-mediated effects.
In support of our hypothesis, the following should be considered: (i) endogenous urea in concentration above 1 mmol/L oxidizes tissue thiol groups in proteins forming disulfide bonds and changing adrenergic receptor activity; urea demonstrates "antifatigue capacity better than L-cysteine" (8, 9) , (ii) in agreement with Kushner (10) we propose that the disruption of one or two hydrogen bonds in a single alpha-helix in protein structure is not enough for an initial protein structural transition; at least three hydrogen bonds are necessary to be broken. That is why it could be accepted that endogenous urea breaks Endogenous urea as endocoid even more than three hydrogen bonds in helix structures of beta-adrenergic receptors (6,7), (iii) "urea can break hydrogen bonds in aminoacid chains of protein receptor structure" and via these molecular events is able to change receptor structure and function (11), (iv) urea at decreased concentrations (2000-60 mmoles/L) inhibits the glucagon-sensitive adenylate cyclase system in plasma membranes of rat liver (12) , and (v) united efforts of French pharmacologists and nephrologists in their research at the beginning paid attention to parathormone for its "anti-beta adrenoreceptor blockade activity of plasma ultra filtrate in two uremic patients" (13); later these authors supposed that "some endogenous substances like creatinine, urea and parathormone could be involved" (14) (15) (16) . It is known that endocoids or autacoids are functioning as "own drugs of organism" (17) . We agree with these authors that "new therapeutic benefits may come through the identification and development of specific endocoids, and synthesis of useful analogues of particular endocoids, leading to many therapeutic avenues". The term "endocoid" (endo acoid) or "autacoid" (auto acoid), from Greek, means an endogenous drug. The term should be applied more specifically to indicate an endogenous counterpart to a drug obtained by chemical synthesis or extracted from plants (18) . To meet presently established criteria, however, the endocoid must compete with an exogenous congener for specific recognition sites (e.g. receptors or enzyme active sites) that mediate the response of target cells, and its action must be blocked by a specific exogenous antagonist. Of course, classical examples are the endorphins and enkephalins, with relation to botanical or synthetic opiat drugs. We accept that "a newly described endocoid may represent a previously unrecognized endogenous ligand or a more specifc or even unique ligand for a well defined receptor/mediator system" (18) .
That is why we include the endogenous urea as a first member of group of endogenous beta-adrenergic receptor antagonists (EBARA) (1) (2) (3) (4) (5) (6) (7) (19) (20) (21) . Taking into account the nonspecific beta-adrenergic receptor antagonistic activity of endogenous urea, we propose a new classification:  endogenous nonspecific beta-adrenergic receptor antagonists (ENBARA), including urea, manganese ions, hydrogen peroxide, and L-taurine (reviewed in 6,7), and   endogenous specific beta-adrenergic receptor antagonists (RESBARA), incluing beta-arrestin 1 and 2 being cofactors of five isolated beta-adrenergic receptor kinases (6, 7, 20, (22) (23) (24) (25) (26) (27) (28) (see the Figure) .
